8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2007

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

England and Wales

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0484822

(Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,

Hampshire RG24 8EP England

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               44 1256 894 000

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.  Other Events

     Shire plc has issued the press releases attached hereto as Exhibit 99.01, Exhibit 99.02 and Exhibit 99.03 which are incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibits are filed herewith:

99.01                Press Release dated August 2, 2007

99.02                Press Release dated August 2, 2007

99.03                Press Release dated August 3, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name: Angus Russell
	Title:   Chief Financial Officer

Dated: August 3, 2007

EXHIBIT INDEX
Number	Description
99.01	Press Release dated August 2, 2007
99.02	Press Release dated August 2, 2007
99.03	Press Release dated August 3, 2007

EX-99.1

EXHIBIT 99.01

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United KingdomTel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

2 August 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify):  Revised due to DTR rules – see Section 13

3. Full name of person(s) subject to the notification obligation:	Fidelity International Limited (FIL)
4. Full name of shareholder(s) (if different from 3.):	See attached schedule
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	26th July 2007
6. Date on which issuer notified:	1 August 2007t
7. Threshold(s) that is/are crossed or reached:	5%
8. Notified details:

Registered in England 2883758  Registered Office as above

A: Voting rights attached to shares

Class/type of shares  if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869	27,815,019	27,815,019			27,763,419		4.99%

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument Expiration date Exercise/Conversion Period/ Date Number of voting rights that may be acquired if  the instrument is exercised/converted % of voting rights

Total (A+B)
Number of voting rights	% of voting rights
27,763,419	4.99%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

See attached schedule

Proxy Voting:

10. Name of the proxy holder:	Fidelity International Limited (FIL)
11. Number of voting rights proxy holder will cease to hold:	51,600
12. Date on which proxy holder will cease to hold voting rights:	26th July 2007

13. Additional information:	None
14. Contact name:	Sophie Hughes
15. Contact:	fil-regulatoryreporting@uk.fid-intl.com

(Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276)

Schedule:

Shares Held	Nominee	Management Company
358,657	Bank of New York Brussels	FPM
642,200	Bank o f New York Europe LDN	FII
327,057	Bermuda Trust Far East HK	FIMHK
82,500	BNP Paribas, Paris ©	FIL
12,316,709	Brown Bros Harrimn Ltd LUX	FIL

Registered in England 2883758  Registered Office as above

79,200	Brown Brothers Harriman and Co	FIL
33,100	Chase Manhttn Bk AG Frnkfrt (S	FPM
23,000	HSBC Trinkaux Und Burkh AG	FIL
677,781	JP Morgan, Bournemouth	FII
2,688,901	JP Morgan, Bournemouth	FIL
8,158,259	JP Morgan Bournemouth	FISL
747,828	JP Morgan Bournemouth	FPM
107,300	Master Trust Bank of Japan	FIJ
60,800	Nomura Trust and Banking	FIJ
24,500	Norddeutsche Landersbank	FIL
83,400	Northern Trust Co	FIL
239,800	Northern Trust London	FIL
906,997	Northern Trust London	FPM
62,800	State Str Bk and Tr Co Lndn (S)	FIL
44,730	State Str Bk and Tr Co Lndn (S)	FPM
118,100	State Street Hong Kong	FIA(K) L

Fidelity International Limited (FIL) is the parent holding company for various direct and indirect subsidiaries, including Fidelity Fund Management Limited (FFML), Fidelity Fund Management Limited (FFML), Fidelity Investment Services Ltd (FISL), Fidelity Gestion (FIGEST), Fidelity Investments Advisory (Korea) Limited (FIAKL), Fidelity Investments Management (Hong Kong) Limited (FIMHK), Fidelity Pension Management (FPM), Fidelity Investments Japan (FLJ) and Fidelity Investments International (FII), investment managers for various non-US investment companies and institutional clients.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758  Registered Office as above

EX-99.2

EXHIBIT 99.02

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United KingdomTel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

2 August 2007

Shire plc (the "Company")

Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities.

The Company was notified by Dr Eliseo Salinas, Executive Vice President, Global Research and Development and Chief Scientific Officer on 1 August 2007, of the exercise in London on the same day, of an option over 105,000 ordinary 5p shares in the capital of the Company at an exercise price of £4.805.  Dr Salinas chose to use a net settled cashless exercise facility run by the Company which resulted in a total of 63,677 shares being allotted to him.  The option over the remaining 41,323 shares lapsed.

The Company was further notified, by Dr Salinas, on 1 August 2007, of the sale in London on the same day of 63,677 ordinary 5p shares in the capital of the Company at a price of £12.21.

Following this transaction Dr Salinas retains share options and stock appreciation rights over a total of 221,005 ordinary shares in the Company.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.  The structure is sufficiently flexible to allow Shire

Registered in England 2883758  Registered Office as above

 to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758  Registered Office as above

EX-99.3

EXHIBIT 99.03

Hampshire International Business Park Chineham  Basingstoke Hampshire RG24 8EP United KingdomTel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

3 August 2007

Shire plc (the "Company")

Notification of the Exercise of an Option and Sale of Shares by a Director.

The Company was notified by Mr Angus Russell, Chief Financial Officer, on 2 August 2007, of the exercise in London on the same day, of an option over 95,285 ordinary 5p shares in the capital of the Company at an exercise price of £5.26.  Mr Russell chose to use a net settled cashless exercise facility run by the Company which resulted in a total of 54,930 shares being allotted to him.  The option over the remaining 40,355 shares lapsed.

The Company was further notified by Mr Russell on 2 August 2007, of the sale in London on the same day of 54,930 ordinary 5p shares in the capital of the Company at a price of £12.42.

Following this transaction Mr Russell retains share options and stock appreciation rights over a total of 1,077,203 ordinary shares in the Company.

T May

Company Secretary

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160
	Eric Rojas (North America)	+1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases.  The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Registered in England 2883758  Registered Office as above

Shire’s focused strategy is to develop and market products for specialty physicians.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758  Registered Office as above